Paper · 36939655
References170
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 170
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30905643 | Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. | Ophthalmology | 2019 | https://conductscience.org/library/papers/30905643 | PubMed |
| 2 | 3802833 | Meta-analysis in clinical trials. | Control Clin Trials | 1986 | https://conductscience.org/library/papers/3802833 | PubMed |
| 3 | 19668420 | Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. | Clin Ophthalmol | 2008 | https://conductscience.org/library/papers/19668420 | PubMed |
| 4 | 29135802 | PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. | Retina | 2019 | https://conductscience.org/library/papers/29135802 | PubMed |
| 5 | 2062513 | Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. | Ophthalmology | 1991 | https://conductscience.org/library/papers/2062513 | PubMed |
| 6 | 30834517 | Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/30834517 | PubMed |
| 7 | 26630313 | INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. | Retina | 2016 | https://conductscience.org/library/papers/26630313 | PubMed |
| 8 | 2866759 | Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. | Arch Ophthalmol | 1985 | https://conductscience.org/library/papers/2866759 | PubMed |
| 9 | 2684072 | Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? | Arch Intern Med | 1989 | https://conductscience.org/library/papers/2684072 | PubMed |
| 10 | 19699531 | Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. | Ophthalmology | 2009 | https://conductscience.org/library/papers/19699531 | PubMed |
| 11 | 11549592 | Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. | Am J Pathol | 2001 | https://conductscience.org/library/papers/11549592 | PubMed |
| 12 | 20606024 | Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. | Br J Ophthalmol | 2010 | https://conductscience.org/library/papers/20606024 | PubMed |
| 13 | 33631120 | Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis. | Can J Ophthalmol | 2021 | https://conductscience.org/library/papers/33631120 | PubMed |
| 14 | 35257962 | Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. | Ophthalmol Retina | 2022 | https://conductscience.org/library/papers/35257962 | PubMed |
| 15 | 23370902 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. | JAMA Ophthalmol | 2013 | https://conductscience.org/library/papers/23370902 | PubMed |
| 16 | 11126403 | Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. | Diabetologia | 2000 | https://conductscience.org/library/papers/11126403 | PubMed |
| 17 | 27034822 | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. | J Ophthalmol | 2016 | https://conductscience.org/library/papers/27034822 | PubMed |
| 18 | 28492920 | Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. | JAMA Ophthalmol | 2017 | https://conductscience.org/library/papers/28492920 | PubMed |
| 19 | 16508426 | Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. | Retina | 2006 | https://conductscience.org/library/papers/16508426 | PubMed |
| 20 | 13129861 | Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. | Ophthalmology | 2003 | https://conductscience.org/library/papers/13129861 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36939655/references